Glooko has announced the appointments of Dr. David Pass and Adam Hameed as the newly-created roles of presidents of Life Sciences and Connected Care, respectively.

Glooko宣布任命DavidPass博士和AdamHameed博士分别担任生命科学和关联护理总裁。

Dr. Pass has extensive experience in pharmaceuticals, medical devices , and healthcare technology. He was previously chief operating officer and chief commercial officer at Gelesis and VP of marketing at Boehringer Ingelheim (BI) for diabetes. At BI he built a multi-billion-dollar alliance with Eli Lilly & Company..

Pass博士在制药、医疗器械和医疗技术方面拥有丰富的经验。他曾任Gelesis首席运营官和首席商务官，以及勃林格殷格翰（BI）糖尿病营销副总裁。在BI，他与礼来公司建立了数十亿美元的联盟。。

Hameed previously served as chief growth officer of Andros, as well as chief development officer of Cricket Health (now part of Interwell Health). Before that, he had leadership positions at Optum, leading payer sales and account management for OptumHealth and several go-to-market teams at OptumInsight..

哈米德曾担任安德罗斯的首席增长官，以及蟋蟀健康（现为Interwell Health的一部分）的首席发展官。在此之前，他曾在Optum担任领导职务，领导OptumHealth的付款人销售和账户管理，以及OptumInsight的几个上市团队。。

Glooko said by creating these new positions it poises itself for further growth and innovation in chronic condition management. The new roles, the Palo Alto, Calif.-based company said, emphasize its commitment to digital companions/therapeutics, clinical research, real-world data, and device integrations..

Glooko说，通过创建这些新职位，它为慢性病管理的进一步发展和创新做好了准备。这家总部位于加利福尼亚州帕洛阿尔托的公司表示，新角色强调了其对数字伴侣/治疗、临床研究、现实世界数据和设备集成的承诺。。

'We are thrilled to welcome David and Adam as Presidents of Life Sciences and Connected Care,' said Russ Johannesson, CEO of Glooko. 'With David and Adam leading our market facing strategies for these differentiated business units, we are confident that their unique experience and close collaboration will help Glooko drive significant new value for our customers, users and partners globally.'.

Glooko首席执行官鲁斯·约翰内斯森（RussJohannesson）说，我们很高兴欢迎戴维（David）和亚当（Adam）担任生命科学和互联医疗（Connected Care）的总裁由于David和Adam领导了我们针对这些差异化业务部门的面向市场战略，我们相信他们独特的经验和密切的合作将有助于Glooko为我们的全球客户、用户和合作伙伴创造重大的新价值。”。

About Glooko

关于Glooko

The company’s personalized, intelligent, connected care platform aims to improve health outcomes of people suffering from chronic conditions. Its technologies seek to drive patient engagement and adherence with digital therapeutics and accelerating the speed of clinical trials.

该公司的个性化、智能化、互联护理平台旨在改善慢性病患者的健康状况。其技术旨在推动患者参与和坚持数字治疗，并加快临床试验的速度。

Using Glooko, data can be synced from a meter, insulin pump or pen, continuous glucose monitor (CGM), food app, activity tracker, and blood pressure device to view all data in one location. Meals and activity can be logged, and the company’s food database contains more than 500,000 items.

使用Glooko，可以从仪表、胰岛素泵或笔、连续血糖监测仪（CGM）、食品应用程序、活动跟踪器和血压设备同步数据，以查看一个位置的所有数据。可以记录膳食和活动，该公司的食品数据库包含50多万个项目。

Glooko is globally deployed in over 30 countries and 8,000+ clinical locations, the company says. It began partnerships with digital therapeutics company Hedia and multinational healthcare and pharmaceutical company Sanofi last year.

该公司表示，Glooko在全球30多个国家和8000多个临床地点部署。去年，它开始与数字治疗公司Hedia和跨国医疗保健和制药公司赛诺菲合作。